Cargando…
The truth of the matter: will immune-tolerant chronic hepatitis B patients benefit from antiviral treatment?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931031/ https://www.ncbi.nlm.nih.gov/pubmed/36790353 http://dx.doi.org/10.1097/HC9.0000000000000060 |
| _version_ | 1784889159898365952 |
|---|---|
| author | Jeng, Wen-Juei Wong, Grace Lai-Hung |
| author_facet | Jeng, Wen-Juei Wong, Grace Lai-Hung |
| author_sort | Jeng, Wen-Juei |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9931031 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-99310312023-03-16 The truth of the matter: will immune-tolerant chronic hepatitis B patients benefit from antiviral treatment? Jeng, Wen-Juei Wong, Grace Lai-Hung Hepatol Commun Editorials Lippincott Williams & Wilkins 2023-02-14 /pmc/articles/PMC9931031/ /pubmed/36790353 http://dx.doi.org/10.1097/HC9.0000000000000060 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (https://creativecommons.org/licenses/by/4.0/) (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) |
| spellingShingle | Editorials Jeng, Wen-Juei Wong, Grace Lai-Hung The truth of the matter: will immune-tolerant chronic hepatitis B patients benefit from antiviral treatment? |
| title | The truth of the matter: will immune-tolerant chronic hepatitis B patients benefit from antiviral treatment? |
| title_full | The truth of the matter: will immune-tolerant chronic hepatitis B patients benefit from antiviral treatment? |
| title_fullStr | The truth of the matter: will immune-tolerant chronic hepatitis B patients benefit from antiviral treatment? |
| title_full_unstemmed | The truth of the matter: will immune-tolerant chronic hepatitis B patients benefit from antiviral treatment? |
| title_short | The truth of the matter: will immune-tolerant chronic hepatitis B patients benefit from antiviral treatment? |
| title_sort | truth of the matter: will immune-tolerant chronic hepatitis b patients benefit from antiviral treatment? |
| topic | Editorials |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931031/ https://www.ncbi.nlm.nih.gov/pubmed/36790353 http://dx.doi.org/10.1097/HC9.0000000000000060 |
| work_keys_str_mv | AT jengwenjuei thetruthofthematterwillimmunetolerantchronichepatitisbpatientsbenefitfromantiviraltreatment AT wonggracelaihung thetruthofthematterwillimmunetolerantchronichepatitisbpatientsbenefitfromantiviraltreatment AT jengwenjuei truthofthematterwillimmunetolerantchronichepatitisbpatientsbenefitfromantiviraltreatment AT wonggracelaihung truthofthematterwillimmunetolerantchronichepatitisbpatientsbenefitfromantiviraltreatment |